About: Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease
Creator	Gahlawat, Anuj Garg, Prabha Kumar, Navneet Kumar, Rajender Sandhu, Hardeep Singh, Pal Singh, Saranjit Sjostedt, Anders
Source	Medline; PMC
abstract	[Image: see text] The COVID-19 disease is caused by a new strain of the coronavirus family (SARS-CoV-2), and it has affected at present millions of people all over the world. The indispensable role of the main protease (M(pro)) in viral replication and gene expression makes this enzyme an attractive drug target. Therefore, inhibition of SARS-CoV-2 M(pro) as a proposition to halt virus ingression is being pursued by scientists globally. Here we carried out a study with two objectives: the first being to perform comparative protein sequence and 3D structural analysis to understand the effect of 12 point mutations on the active site. Among these, two mutations, viz., Ser46 and Phe134, were found to cause a significant change at the active sites of SARS-CoV-2. The Ser46 mutation present at the entrance of the S5 subpocket of SARS-CoV-2 increases the contribution of other two hydrophilic residues, while the Phe134 mutation, present in the catalytic cysteine loop, can cause an increase in catalytic efficiency of M(pro) by facilitating fast proton transfer from the Cys145 to His41 residue. It was observed that active site remained conserved among M(pro) of both SARS-CoVs, except at the entrance of the S5 subpocket, suggesting sustenance of substrate specificity. The second objective was to screen the inhibitory effects of three different data sets (natural products, coronaviruses main protease inhibitors, and FDA-approved drugs) using a structure-based virtual screening approach. A total of 73 hits had a combo score >2.0. Eight different structural scaffold classes were identified, such as one/two tetrahydropyran ring(s), dipeptide/tripeptide/oligopeptide, large (approximately 20 atoms) cyclic peptide, and miscellaneous. The screened hits showed key interactions with subpockets of the active site. Further, molecular dynamics studies of selected screened compounds confirmed their perfect fitting into the subpockets of the active site. This study suggests promising structures that can fit into the SARS-CoV-2 M(pro) active site and also offers direction for further lead optimization and rational drug design.
has issue date	2020-07-20(xsd:dateTime)
bibo:doi	10.1021/acs.jcim.0c00546
bibo:pmid	32687345
has license	no-cc
sha1sum (hex)	c7d2a3106b23a26f546836cf59e661794f6c7ae1
schema:url	https://doi.org/10.1021/acs.jcim.0c00546
resource representing a document's title	Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease
has PubMed Central identifier	PMC7409927
has PubMed identifier	32687345
schema:publication	J Chem Inf Model
resource representing a document's body	covid:c7d2a3106b23a26f546836cf59e661794f6c7ae1#body_text
is schema:about of	named entity 'halt' named entity 'compounds' named entity 'proposition' named entity 'drug target' named entity 'disease' named entity 'globally' named entity 'screen' named entity 'ring' named entity 'atoms' named entity 'virus' named entity 'Lead' named entity 'structure-based' named entity 'rational drug design' named entity 'attractive' named entity 'structural' named entity 'point mutations' named entity 'catalytic' named entity 'caused' named entity 'indispensable' named entity 'viral replication' named entity 'mutation' named entity 'oligopeptide' named entity 'COVID-19' named entity 'effects' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'oligopeptide' named entity 'active site' named entity 'substrate specificity' named entity 'SARS-CoV-2' named entity 'mutation' named entity 'proton' named entity 'SARS-CoV-2' named entity 'tripeptide' named entity 'active site' named entity 'coronavirus' named entity 'cyclic peptide' named entity 'protease inhibitors' named entity 'SARS-CoV-2' named entity 'active sites' named entity 'rational drug design' named entity 'SARS-CoV-2' named entity 'Structure-Based' named entity 'substrate specificity' named entity 'active site' named entity 'SARS-CoV' named entity 'virtual screening' named entity 'delphinidin' named entity 'proteases' named entity 'binding affinity' named entity 'GBSA' named entity 'RMSD' named entity 'GBSA' named entity 'ligand' named entity 'flavonoids' named entity 'ligands' named entity 'mutation' named entity 'molecular dynamics' named entity 'catechol' named entity 'SARS-CoV-2' named entity 'acteoside' named entity 'quantum methods' named entity 'proteolysis' named entity 'HKU1' named entity 'nucleus' named entity 'virtual screening' named entity 'protease inhibitors' named entity 'hydroxy group' named entity 'crystal structure' named entity 'ligand' named entity 'SARS-CoV' named entity 'RMSF' named entity '3,5' named entity 'glucose unit'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software